FDA Approves Use of Up To Three Tubes of Biofrontera Inc.'s Ameluz (aminolevulinic acid HCI) Topical Gel, 10% In One Treatment

• Approval allows for larger field treatment of actinic keratosis (AK) on face and scalp with Ameluz^®-PDT using the BF-RhodoLED or the RhodoLED XL lamp
• Supplemental New Drug Application (sNDA) supported by two Phase 1 safety studies
• AK is the second most common diagnosis made by dermatologists in the United States¹
• An estimated 13 million treatments given each year for AK in the US²

WOBURN, Mass., Oct. 07, 2024 (GLOBE NEWSWIRE) -- Biofrontera Inc. (Nasdaq: BFRI) ("Biofrontera” or the "Company”), a biopharmaceutical company specializing in the commercialization of dermatologic products, today announced that the U.S. Food and Drug Administration (FDA) has approved the Company's sNDA to increase the maximally approved dosage from one to three tubes of Ameluz^® per treatment.